

To: (10)(2e) -UAL 11 BMG[(10)(2e) @bmg.bund.de]; (10)(2e) @pm.gouv.fr[(10)(2e) @pm.gouv.fr]; (10)(2e) @minvws.nl[(10)(2e) @minvws.nl]; (10)(2e) @minvws.nl[(10)(2e) @minvws.nl]; (10)(2e) @unicatt.it[(10)(2e) @unicatt.it]; (10)(2e) @minvws.nl[(10)(2e) @minvws.nl]; (10)(2e) @minvws.nl[(10)(2e) @minvws.nl]; (10)(2e) @igf.finances.gouv.fr[(10)(2e) @igf.finances.gouv.fr]; (10)(2e) @minvws.nl[(10)(2e) @minvws.nl]; (10)(2e) @minvws.nl[(10)(2e) @minvws.nl]

Cc: '11 BMG'[(10)(2e) @bmg.bund.de]; (10)(2e) RL 117 BMG[(10)(2e) @bmg.bund.de]; '113 BMG'[(10)(2e) @bmg.bund.de]; '117 BMG'[(10)(2e) @bmg.bund.de]

From: Ruocco Giuseppe

Sent: Thur 6/25/2020 12:55:31 PM

Subject: R: Agreement re Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe - Funding Agreement

Dear (10)(2e)

we are fully aware that most part of the draft agreement you sent yesterday is already included in the TS signed by Ministers and AZ.

in any case we would like put to your attnetion some comments:



(10)(2a)

Many thanks for your attention
Giuseppe



Dott. Giuseppe RUOCCO
Segretario Generale – Chief Medical Officer
Ministero della salute – Italia
Viale G. Ribotta, 5 – ROMA
Tel. (10)(2e)
Mob. (10)(2e)

Da: (10)(2e) -UAL 11 BMG <(10)(2e) @bmg.bund.de>

Inviato: mercoledì 24 giugno 2020 18:35

A: (10)(2e) @pm.gouv.fr <(10)(2e) @pm.gouv.fr>; (10)(2e) @minvws.nl <(10)(2e) @minvws.nl>; (10)(2e) @minvws.nl <(10)(2e) @minvws.nl>; (10)(2e) @sanita.it <(10)(2e) @sanita.it>; (10)(2e) @unicatt.it <(10)(2e) @unicatt.it>; (10)(2e) @minvws.nl <(10)(2e) @minvws.nl>; (10)(2e) @igf.finances.gouv.fr <(10)(2e) @igf.finances.gouv.fr>; (10)(2e) @minvws.nl <(10)(2e) @minvws.nl>

Cc: 11 BMG <(10)(2e) @bmg.bund.de>; (10)(2e) RL 117 BMG <(10)(2e) @bmg.bund.de>; 113 BMG <(10)(2e) @bmg.bund.de>; 117 BMG <(10)(2e) @bmg.bund.de>

Oggetto: WG: Agreement re Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe - Funding Agreement

Riservatezza: Riservato

Dear all,

please find attached the draft funding agreement. We're happy to receive your comments - and maybe amendments!

In addition: Presumably our Minister will contact your Ministers concerning the involvement of the COM in the AZ agreement, as he communicated with Ursula von der Leyen.

Kind regards

(10)(2e)

-----Ursprüngliche Nachricht-----

Von: (10)(2e) | (10)(2e) @astrazeneca.com]

Gesendet: Mittwoch, 24. Juni 2020 17:27

An: (10)(2e) -RL 117 BMG <(10)(2e) @bmg.bund.de>; (10)(2e) -AL 1 BMG

<(10)(2e) @bmg.bund.de>

Cc: (10)(2e) -UAL 11 BMG <(10)(2e) @bmg.bund.de>

Betreff: RE: Agreement re Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe - Funding Agreement

Vertraulichkeit: Vertraulich

Dear (10)(2e) and (10)(2e) (10)(2e)

As promised, please find our draft proposal re the Funding Agreement. There is still one part open in 'schedule A' re the 'Purchase & Payment schedule' that still needs to be inserted. We plan to send this part next week to you.

Further to my mail below, and since we have signed the Term sheet on June 12th, it would be most appreciated if you could provide me this week with your feedback on my first question below re the invoicing details.

Looking forward to receiving your feedback,

With best regards,

(10)(2e)

(10)(2e)

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

T: (10)(2e) | M: (10)(2e)

(10)(2e) @astrazeneca.com <(10)(2e) @astrazeneca.com>

(10)(2e)

(10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e)
Sent: 18 June 2020 13:52
To: (10)(2e) -RL 117 BMG <(10)(2e)@bmg.bund.de>
Cc: (10)(2e) -AL 1 BMG <(10)(2e)@bmg.bund.de>; (10)(2e) -UAL 11 BMG <(10)(2e)@bmg.bund.de>; (10)(2e) -RL 113 BMG <(10)(2e)@bmg.bund.de>; 113 BMG <(10)(2e)@bmg.bund.de>; 11 BMG <(10)(2e)@bmg.bund.de>; 1 BMG <(10)(2e)@bmg.bund.de>; 117 BMG <(10)(2e)@bmg.bund.de>
Subject: RE: Agreement re Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe - Funding Agreement
Sensitivity: Confidential

Dear (10)(2e) (10)(2e)

Further to our conversation of today, I would like to summarize the questions that we have today:

* Could you please send us asap the name and address of the entity to whom we can send the invoice following the signing of the Term Sheet?

(10)(2a)

* We are proposing to set up a Governance structure for working together in the months to follow. An alliance manager on both sides could help to assure speed and a smooth flow of information and responses between the parties. Please let us know your thoughts on this?

* For the distribution of the vaccine we still need to come to an agreement. It is important to realise that the hubs where the vaccine is shipped to in large quantities, needs to have sufficient cold storage facility. It might be a good idea to contract and work with a single distribution agent for Europe. It would be also good to already get your first view on this.

With best regards,

(10)(2e)

(10)(2e)

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

T: (10)(2e) | M: (10)(2e)

(10)(2e) @astrazeneca.com <(10)(2e)@astrazeneca.com>

(10)(2e)

(10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e)
 Sent: 17 June 2020 08:23
 To: (10)(2e) -RL 117 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>
 Cc: (10)(2e) -AL 1 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; (10)(2e) -UAL 11 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; (10)(2e) -RL 113 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; 113 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; 11 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; 1 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; 117 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>

Subject: RE: Agreement re Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe - Funding Agreement
 Sensitivity: Confidential

Dear Mrs. (10)(2e)

Many thanks for your email. We will start working on this during this week. We have tonight our first team meeting on this and will start preparing a draft Funding Agreement. Can you please confirm that we will have 1 Funding Agreement that will be signed by the 4 Parties of the Coalition Governments, similar to the Term Sheet?

With best regards,

(10)(2e)

(10)(2e)

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

T: (10)(2e) | M: (10)(2e)

(10)(2e)@astrazeneca.com <(10)(2e)@astrazeneca.com>

(10)(2e) : (10)(2e)

(10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e) -RL 117 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>

(10)(2e) @bmg.bund.de>>
 Sent: 16 June 2020 14:10
 To: (10)(2e) <(10)(2e)@astrazeneca.com <(10)(2e)@astrazeneca.com>>
 Cc: (10)(2e) -AL 1 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; (10)(2e) <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; (10)(2e) -RL 113 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; 113 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; 11 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; 1 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>; 117 BMG <(10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>>
 Subject: Agreement re Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe - Funding Agreement
 Sensitivity: Confidential

Dear Mr. (10)(2e)

following our previous discussions and the successfully agreed term sheet we need to conclude the funding agreement as soon as possible. Could you please send us a proposal for a draft funding agreement as a first step, so that we can discuss it with our partners. When will you be able to provide us with it? Please don't hesitate to contact us in case of further questions.

Kind regards

Mit freundlichen Grüßen
 Im Auftrag

Dr. (10)(2e)

Leiterin Referat 117
 Nutzenbewertung, Preisbildung und Erstattung neuer Arzneimittel Bundesministerium für Gesundheit Friedrichstraße 108, 10117
 Berlin

Postanschrift: 11055 Berlin
 Tel.: (10)(2e)
 Fax: (10)(2e)
 Mail: (10)(2e)@bmg.bund.de <(10)(2e)@bmg.bund.de>
 Internet: www.bundesgesundheitsministerium.de <<http://www.bundesgesundheitsministerium.de>>
 Twitter: www.twitter.com/BMG_Bund <http://www.twitter.com/BMG_Bund>
 Facebook: www.facebook.com/BMG.Bund <<http://www.facebook.com/BMG.Bund>>
 Instagram: www.instagram.com/bundesgesundheitsministerium <<http://www.instagram.com/bundesgesundheitsministerium>>

Hinweis zu externen Links.

Auf Art und Umfang der übertragenen bzw. gespeicherten Daten hat das BMG keinen Einfluss.
 Der Schutz Ihrer Daten ist uns wichtig. Nähere Informationen zum Umgang mit personenbezogenen Daten im BMG können Sie der Datenschutzerklärung auf <https://www.bundesgesundheitsministerium.de/datenschutz.html> <<https://www.bundesgesundheitsministerium.de/datenschutz.html>> entnehmen.

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com <<https://www.astrazeneca.com>>